Pfizer partners with Medco on genetic profiling project; FDA delays decision on diabetes drug;

@FierceBiotech: Special Report: 10 Promising Therapeutic Vaccines. Report Most are cancer vaccines. | Follow @FierceBiotech

@JohnCFierce: Headed to Dusseldorf over the weekend to moderate a panel on biopharma/academic collabs. Hot topic these days. | Follow @JohnCFierce

> Pfizer is partnering up with Medco Health Solutions on an effort to better identify subsets of patients most likely to benefit from one of their drugs. They'll be working on experimental as well as marketed drugs. Story

> Bristol-Myers and AstraZeneca will have to wait a little longer before they get final word from the FDA on their application for the diabetes drug dapagliflozin. Regulators are delaying the decision by three months. Article

> Quintiles has been on a buying spree this week. The CRO announced that it snapped up Advion Biosciences, its third deal in recent days. Report

Pharma News

@FiercePharma: New job opportunities emerging in Big Pharma. News | Follow @FiercePharma

> BMS sales up 8%, thanks to drugs new and old. Item

> AZ sales flat on generic rivals, pricing pressures. Story

> FDA ruling against Avastin wouldn't deter half of doctors. More

> Swiss activists plan 'occupy' protest at Novartis chair's house. Piece

Vaccines News

> Gilead, GlobeImmune team up on HBV vaccines. Article

> Diabetics under 60 should get hep B vaccine. Story

> FDA warns against needleless flu shots. Report

> CDC group backs Gardasil for boys. News

> Board considers anthrax vaccine trials for kids. Story

Manufacturing News

> Novartis to cut 2,000 jobs in ops restructuring. Item

> China to ramp up epidemic vax system. Story

> Sanofi licenses hard-to-make asthma drug to Acton. News

> Baxter issues precautionary recall of flu vaccine. Report

And Finally...Investigators say they've been able to track the slow growth of certain regions of the brains of autistic boys. Release

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.